[Featured Stock] IGEN Hits Upper Limit on News of Starting Omicron Vaccine Development

On the 13th, as the spread of COVID-19 continued, citizens are getting tested at a temporary screening clinic set up at Peace Plaza in World Cup Park, Mapo-gu, Seoul. Photo by Mun Ho-nam munonam@

[Asia Economy Reporter Ji Yeon-jin] Aizen surged to the upper limit price early in trading on the 14th following news that it has begun developing a vaccine to respond to the new variant of the coronavirus disease (COVID-19), Omicron.

On the same day, from around 9:16 a.m., Aizen was trading on the KOSDAQ market at 23,100 KRW, up 29.78% compared to the previous day.

The news that it has started developing a vaccine capable of responding to the Omicron variant is interpreted as the reason for the surge to the upper limit price. Jo Yang-je, Aizen's Chief Technology Officer (CTO), said in a recent interview, "We have quickly completed the nucleotide sequence analysis of the Omicron variant," and added, "If only the plasmid DNA, the mRNA raw material, is supplied, we can apply the prepared vaccine design to develop the vaccine."

This content was produced with the assistance of AI translation services.